Full Press Release Details
S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary
PARIS--(BUSINESS WIRE)--May 4, 2015--Regulatory News:
Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS - Nasdaq Global Market:
CLLS) a pioneering gene-editing company employing proprietary
technologies to develop best-in-class products in the emerging field of
immuno-oncology, today announced that it has changed the name of its
subsidiary, Cellectis plant sciences, Inc. to Calyxt, Inc.
The name change is part of Cellectis' effort to further distinguish the
parent company's focus from that of it subsidiary. Gene editing is the
common base of the two companies: it is used by Cellectis in the
development of new and innovative product candidates for treatment of
cancers, and by Calyxt in the development of improved crops for
consumers with healthier characteristics.
The goal of the name change is to leverage the strengths of both
Cellectis and Calyxt brand identities.
To find out more about Calyxt, please visit www.calyxt.com
Cellectis is a gene-editing company focused on developing
immunotherapies based on gene edited engineered CAR-T cells (UCART). The
company's mission is to develop a new generation of cancer therapies
based on engineered T-cells. Cellectis capitalizes on its 15 years of
expertise in genome engineering - based on its flagship TALEN products
and meganucleases and pioneering electroporation PulseAgile technology -
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis' goal is to create innovative products in multiple fields and
with various target markets. Cellectis S.A. is listed on the Nasdaq
Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker:
ALCLS). To find out more about us, visit our website: www.cellectis.com
Jennifer Moore, 917-580-1088
Brad Miles, 646-513-3125
Simon Harnest, 646-385-9008
VP Finance and Investor